Details for Patent: 9,616,028
✉ Email this page to a colleague
Which drugs does patent 9,616,028 protect, and when does it expire?
Patent 9,616,028 protects QTERNMET XR and XIGDUO XR and is included in two NDAs.
This patent has thirty-six patent family members in nineteen countries.
Summary for Patent: 9,616,028
| Title: | Bilayer tablet formulations |
| Abstract: | The present invention relates to bilayer tablet formulations comprising metformin extended release (XR) or reduced mass metformin XR formulation as the first layer, an SGLT2 inhibitor formulation as the second layer, and optionally a film coating. The present invention provides methods of preparing the bilayer tablet formulations and methods of treating diseases or disorders associated with SGLT2 activity employing the bilayer tablet formulations. |
| Inventor(s): | Abebe; Admassu (Princeton, NJ), Martin; Kyle (Princeton, NJ), Patel; Jatin M. (Princeton, NJ), Desai; Divyakant (Princeton, NJ), Timmins; Peter (Moreton, GB) |
| Assignee: | AstraZeneca AB (Sodertalje, SE) AstraZeneca UK Limited (London, GB) |
| Application Number: | 14/706,077 |
|
Patent Claim Types: see list of patent claims | Formulation; Compound; Dosage form; |
Drugs Protected by US Patent 9,616,028
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Astrazeneca Ab | QTERNMET XR | dapagliflozin; metformin hydrochloride; saxagliptin hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 210874-001 | May 2, 2019 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
| Astrazeneca Ab | QTERNMET XR | dapagliflozin; metformin hydrochloride; saxagliptin hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 210874-002 | May 2, 2019 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
| Astrazeneca Ab | QTERNMET XR | dapagliflozin; metformin hydrochloride; saxagliptin hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 210874-003 | May 2, 2019 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
| Astrazeneca Ab | QTERNMET XR | dapagliflozin; metformin hydrochloride; saxagliptin hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 210874-004 | May 2, 2019 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
| Astrazeneca Ab | XIGDUO XR | dapagliflozin; metformin hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 205649-005 | Jul 28, 2017 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 9,616,028
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 2498758 | ⤷ Sign Up | 301040 | Netherlands | ⤷ Sign Up |
| European Patent Office | 2498758 | ⤷ Sign Up | LUC00152 | Luxembourg | ⤷ Sign Up |
| European Patent Office | 2498758 | ⤷ Sign Up | PA2020003 | Lithuania | ⤷ Sign Up |
| European Patent Office | 2498758 | ⤷ Sign Up | CA 2020 00017 | Denmark | ⤷ Sign Up |
| European Patent Office | 2498758 | ⤷ Sign Up | 2020C/509 | Belgium | ⤷ Sign Up |
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
